aprepitant
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
pharma · Analgesia · Postoperative Pain · HRTX
Heron Therapeutics
Heron Therapeutics drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
100 Regency Forest Dr, Cary, North Carolina 27518, US HQ
1983 Founded
188 Employees
Public company Type
HRTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 100 Regency Forest Dr, Cary, North Carolina 27518, US
- Founded
- 1983
- Employees
- 188
- Programs
- 18
- Drugs
- 17
- Patents
- 46
Heron Therapeutics pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Heron Therapeutics drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
bupivacaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
Development asset linked to Heron Therapeutics in public FDA and regional records.
-
Development asset linked to Heron Therapeutics in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Heron Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
Development asset linked to Heron Therapeutics in public FDA and regional records.
-
granisetron
Alimentary tract and metabolism (A04)US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
- Target
- 5-hydroxytryptamine receptor 3A
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
Development asset linked to Heron Therapeutics in public FDA and regional records.
-
Development asset linked to Heron Therapeutics in public FDA and regional records.
-
Development asset linked to Heron Therapeutics in public FDA and regional records.
-
Development asset linked to Heron Therapeutics in public FDA and regional records.
-
Development asset linked to Heron Therapeutics in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Heron Therapeutics in public FDA and regional records.
-
Development asset linked to Heron Therapeutics in public FDA and regional records.
-
Development asset linked to Heron Therapeutics in public FDA and regional records.